Analysis: Mike Kelly's sell of ABT (Abbott Laboratories)

Assessment: On watch

Rep. Mike Kelly's sell of Abbott Laboratories occurred immediately after a positive public earnings release and alongside other blue-chip sales, indicating a routine portfolio rebalance rather than a policy-informed trade.

Executive summary

This research packet documents Rep. Mike Kelly’s disclosed sale of Abbott Laboratories (ABT) on 2026-07-17 ($1,001-$15,000; self), disclosed on 2026-08-12 (26-day lag). Nearby public-company context includes Abbott’s 8-K filed 2026-07-16 announcing Q2 2026 results and raising full-year adjusted EPS guidance, and limited available federal activity context includes Ways and Means committee hearings/markup and healthcare supply-chain transparency bills (not Abbott-specific) found on Congress.gov.

On 2026-07-16 (one day before the trade), Abbott filed an 8-K stating it announced second-quarter 2026 results and furnished an Exhibit 99.1 press release that includes raised full-year adjusted diluted EPS guidance. The member’s trade date (2026-07-17) coincides with a same-day batch of two other sales (DIS and PEP) per user-provided data. Congress.gov sources retrieved in this session include Ways and Means Committee hearing listings during 2026 (including Health and Tax-related hearings) and a Ways and Means markup listed on the Congress.gov committee schedule for 2026-07-15. In the available insider-transaction window provided, Abbott Form 4 activity included one open-market purchase by a director (2026-05-07), multiple grants/withholdings around late June 2026, and an EVP sale dated 2026-08-11. Federal Register pages were accessible only via CAPTCHA in this environment; one Abbott-titled document URL dated 2026-08-06 (FTZ production activity notification) was identified but its SUMMARY/effective dates/comment deadlines could not be extracted.

Timeline

Independent analysis of public financial disclosures. Not financial or investment advice.

Sources

  1. Mike Kelly | Congress.gov
  2. Congressman Mike Kelly | - House.gov
  3. Member IDs for Biographical Directory - Congress.gov
  4. Mike Kelly - USQuery
  5. OurCongress
  6. Infant Formula Shortage: FDA Regulation and Federal ...
  7. Infant Formula Shortage: FDA Regulation and Federal Response
  8. MEMORANDUM May 23, 2022 To: Subcommittee on Oversight and Investigations Members and Staff Fr: Committee on Energy and Commerce Staff Re: Hearing on “Formula Safety and Supply: Protecting the Health of America’s Babies” On Wednesday, May 25, 2022, at 11 a.m. (EDT), in the John D. Dingell Room, 2123 of the Rayburn House Office Building, and via Cisco WebEx online video conferencing, the Subcommittee on Oversight and Investigations will hold a hearing entitled, “Formula Safety and Supply: Protecting the Health of America’s Babies.” The hearing will examine the nation’s infant formula product recall, shortage, steps taken to increase supply, and what further action is necessary to ensure families’ access to safe formula across the country. I. BACKGROUND In recent months, American families have experienced a supply shortage of infant formula. Reports of a shortage first began in January 2022, which was exacerbated by the Abbott Nutrition (Abbott) voluntary recall of certain brands of powdered infant formula in (Cronobacter) contamination at its Sturgis, Michigan, facility. As many as 75 percent of American caregivers partially depend on formula to provide nutrients to their infants up to six-months of age. 3 The current shortage has been particularly acute for low-income families, rural families, and infants and children solely reliant on specialty formulas to manage metabolic, gastrointestinal, or allergic disorders.
  9. Drug Pricing and Intellectual Property: The Legislative ...
  10. Daily Digest
  11. Text - S.3788 - 119th Congress (2025-2026): CLEAR LABELS Act | Congress.gov | Library of Congress
  12. Text - H.R.8339 - 119th Congress (2025-2026): Drug Origin Transparency Act of 2026 | Congress.gov | Library of Congress
  13. https://www.congress.gov/119/bills/hr8269/BILLS-119hr8269ih.htm
  14. H. R. 8890
  15. H. R. 5269
  16. abt-20251231
  17. EDGAR Filing Documents for 0001628280-26-010185 - SEC.gov
  18. 0001628280-26-010185 | 10-K | Abbott Laboratories - Annual Reports
  19. View Filing Data
  20. EDGAR Search Results
  21. EDGAR Search Results
  22. EDGAR Search Results
  23. EDGAR Search Results
  24. EDGAR Search Results
  25. EDGAR Search Results
  26. Foreign-Trade Zone (FTZ) 39, Notification of Proposed ...
  27. Federal Register Document Issue for 2026-08-06
  28. Drugs for Human Use; Drug Efficacy Study Implementation ...
  29. 08/05/2026 Public Inspection Issue
  30. 2026 Federal Register Index :: Foreign-Trade Zones Board
  31. ABBOTT MOLECULAR INC. | Federal Award Recipient Profile
  32. ABBOTT RAPID DX NORTH AMERICA LLC - USAspending.gov
  33. ABBOTT DIABETES CARE SALES CORP | Federal Award Recipient ...
  34. ALERE TOXICOLOGY SERVICES, INC | Federal Award Recipient Profile
  35. ST. JUDE MEDICAL, LLC | Federal Award Recipient Profile
  36. Comment from Abbott Laboratories
  37. Comments
  38. Federal Register, Volume 77 Issue 53 (Monday, March 19, 2012)
  39. Federal Register, Volume 90 Issue 151 (Friday, August 8, 2025)
  40. Federal Register, Volume 90 Issue 230 (Wednesday, December 3, 2025)
  41. abt-20260716
  42. Document
  43. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance - Jul 16, 2026
  44. Abbott Reports Second-Quarter 2026 Results and Raises Full ...
  45. Abbott Reports Second-Quarter 2026 Results and Raises ...
  46. Committee Schedule for 07/15/2026 | Congress.gov
  47. Committee Schedule for 07/21/2026 | Congress.gov
  48. Committee Schedule for 07/14/2026 | Congress.gov
  49. Hearings - Ways and Means Committee
  50. Committee Schedule for 07/16/2026 | Congress.gov | Library of Congress
  51. sec.gov
  52. sec.gov
  53. sec.gov
  54. sec.gov

Mike Kelly · ABT · Trading news